PubMed=19920829; DOI=10.1038/sj.bjc.6605448; PMCID=PMC2813756
Karim S. El-Sahwi, Stefania Bellone, Emiliano Cocco, Marilisa Cargnelutti, Francesca Casagrande, Marta Bellone, Maysa Abu-Khalaf, Natalia Buza, Fattaneh A. Tavassoli, Pei Hui, Dan-Arin Silasi ...Show all 16 authors... , Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Alessandro D. Santin; Show fewer authors
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
Br. J. Cancer 102:134-143(2010)

PubMed=21246534; DOI=10.1002/cncr.25891; PMCID=PMC3128671
Joyce Varughese, Emiliano Cocco, Stefania Bellone, Maria de Leon, Marta Bellone, Paola Todeschini, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Alessandro D. Santin;
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Cancer 117:3163-3172(2011)

PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020
Diana P. English, Stefania Bellone, Emiliano Cocco, Ileana Bortolomai, Sergio Pecorelli, Salvatore Lopez, Dan-Arin Silasi, Peter E. Schwartz, Thomas J. Rutherford, Alessandro D. Santin;
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013)